These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 12121563

  • 1. Treatment of cutaneous leishmaniasis with a combination of allopurinol and low-dose meglumine antimoniate.
    Momeni AZ, Reiszadae MR, Aminjavaheri M.
    Int J Dermatol; 2002 Jul; 41(7):441-3. PubMed ID: 12121563
    [Abstract] [Full Text] [Related]

  • 2. Treatment of recurrent cutaneous Leishmaniasis.
    Momeni AZ, Aminjavaheri M.
    Int J Dermatol; 1995 Feb; 34(2):129-33. PubMed ID: 7737774
    [Abstract] [Full Text] [Related]

  • 3. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.
    Nilforoushzadeh MA, Jaffary F, Ansari N, Siadat AH, Nilforoushan Z, Firouz A.
    J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655
    [Abstract] [Full Text] [Related]

  • 4. Allopurinol in the treatment of American cutaneous leishmaniasis.
    Martinez S, Marr JJ.
    N Engl J Med; 1992 Mar 12; 326(11):741-4. PubMed ID: 1738379
    [Abstract] [Full Text] [Related]

  • 5. Treatment of cutaneous leishmaniasis recidivans with a combination of allopurinol and meglumine antimoniate: a clinical and histologic study.
    Esfandiarpour I, Dabiri SH.
    Int J Dermatol; 2007 Aug 12; 46(8):848-52. PubMed ID: 17651170
    [Abstract] [Full Text] [Related]

  • 6. Successful treatment of non-healing cases of cutaneous leishmaniasis, using a combination of meglumine antimoniate plus allopurinol.
    Momeni AZ, Aminjavaheri M.
    Eur J Dermatol; 2003 Aug 12; 13(1):40-3. PubMed ID: 12609780
    [Abstract] [Full Text] [Related]

  • 7. Low dosage combination of meglumine antimoniate plus allopurinol as first choice treatment of infantile visceral leishmaniasis in Italy.
    di Martino L, Mantovani MP, Gradoni L, Gramiccia M, Guandalini S.
    Trans R Soc Trop Med Hyg; 1990 Aug 12; 84(4):534-5. PubMed ID: 2091347
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial.
    Velez I, Agudelo S, Hendrickx E, Puerta J, Grogl M, Modabber F, Berman J.
    Ann Intern Med; 1997 Feb 01; 126(3):232-6. PubMed ID: 9027276
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Assessment of allopurinol plus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV.
    Laguna F, López-Vélez R, Soriano V, Montilla P, Alvar J, González-Lahoz JM.
    J Infect; 1994 May 01; 28(3):255-9. PubMed ID: 8089514
    [Abstract] [Full Text] [Related]

  • 12. Evaluating the efficacy of allopurinol and meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis.
    Esfandiarpour I, Alavi A.
    Int J Dermatol; 2002 Aug 01; 41(8):521-4. PubMed ID: 12207774
    [Abstract] [Full Text] [Related]

  • 13. A comparative study between the efficacy of oral cimetidine and low-dose systemic meglumine antimoniate (MA) with a standard dose of systemic MA in the treatment of cutaneous leishmaniasis.
    Shanehsaz SM, Ishkhanian S.
    Int J Dermatol; 2015 Jul 01; 54(7):834-8. PubMed ID: 26108265
    [Abstract] [Full Text] [Related]

  • 14. Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial.
    Firooz A, Khamesipour A, Ghoorchi MH, Nassiri-Kashani M, Eskandari SE, Khatami A, Hooshmand B, Gorouhi F, Rashighi-Firoozabadi M, Dowlati Y.
    Arch Dermatol; 2006 Dec 01; 142(12):1575-9. PubMed ID: 17178983
    [Abstract] [Full Text] [Related]

  • 15. Comparative histological and immunohistochemical changes of dry type cutaneous leishmaniasis after administration of meglumine antimoniate, imiquimod or combination therapy.
    Shamsi Meymandi S, Javadi A, Dabiri S, Shamsi Meymandi M, Nadji M.
    Arch Iran Med; 2011 Jul 01; 14(4):238-43. PubMed ID: 21726098
    [Abstract] [Full Text] [Related]

  • 16. Response of cutaneous leishmaniasis (chiclero's ulcer) to treatment with meglumine antimoniate in Southeast Mexico.
    Vargas-Gonzalez A, Canto-Lara SB, Damian-Centeno AG, Andrade-Narvaez FJ.
    Am J Trop Med Hyg; 1999 Dec 01; 61(6):960-3. PubMed ID: 10674678
    [Abstract] [Full Text] [Related]

  • 17. Chronic zosteriform cutaneous leishmaniasis.
    Omidian M, Mapar MA.
    Indian J Dermatol Venereol Leprol; 2006 Dec 01; 72(1):41-2. PubMed ID: 16481709
    [Abstract] [Full Text] [Related]

  • 18. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis.
    Moosavi Z, Nakhli A, Rassaii S.
    Int J Dermatol; 2005 Dec 01; 44(12):1064-5. PubMed ID: 16409282
    [No Abstract] [Full Text] [Related]

  • 19. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru.
    Miranda-Verástegui C, Llanos-Cuentas A, Arévalo I, Ward BJ, Matlashewski G.
    Clin Infect Dis; 2005 May 15; 40(10):1395-403. PubMed ID: 15844060
    [Abstract] [Full Text] [Related]

  • 20. Intralesional Infiltration with Meglumine Antimoniate for the Treatment of Leishmaniasis Recidiva Cutis in Ecuador.
    Calvopiña M, Cevallos W, Paredes Y, Puebla E, Flores J, Loor R, Padilla J.
    Am J Trop Med Hyg; 2017 Nov 15; 97(5):1508-1512. PubMed ID: 29016328
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.